Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT02738554 Completed - Chronic Hepatitis B Clinical Trials

Off Treatment Durability in Chronic Hepatitis B With Good Immune Control

Start date: January 2016
Phase: N/A
Study type: Interventional

Treatment cessation in chronic hepatitis B is associated with high rates of disease relapse. However patients who achieve the seroclearance of hepatitis B surface antigen (HBsAg) (<0.05 IU/mL) show good off-treatment durability after treatment cessation. Through the quantification of HBsAg, the study aims to investigate how low should quantitative HBsAg be before once can achieve successful disease control after treatment cessation.

NCT ID: NCT02738138 Completed - Chronic Hepatitis C Clinical Trials

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)

EXPEDITION-2
Start date: May 17, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1-6 infection and human immunodeficiency virus-1 co-infection.

NCT ID: NCT02738008 Terminated - Hepatitis B Clinical Trials

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Start date: March 2016
Phase: Phase 2
Study type: Interventional

Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.

NCT ID: NCT02732639 Completed - Clinical trials for Hepatitis D, Chronic

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Start date: October 2005
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD). Treatment will be followed by 24 weeks of treatment-free follow-up.

NCT ID: NCT02732054 Completed - Hepatitis B Clinical Trials

Hepatitis B Vaccination in HIV-infected Adults With Low CD4 Cell Counts

Start date: March 2015
Phase: Phase 4
Study type: Interventional

This study aimed to evaluate the efficacy of different hepatitis B vaccination regimens in HIV-infected adults with low CD4 cell count in northern Thailand.

NCT ID: NCT02731131 Completed - Clinical trials for Hepatitis D, Chronic

A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination with ribavirin in participants with CHD.

NCT ID: NCT02726789 Completed - Clinical trials for Hepatitis B, Chronic

Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

Start date: October 2012
Phase: Phase 2
Study type: Interventional

The REP 201 protocol is a small exploratory study assessing the antiviral effects and tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks) in treatment naive patients or in patients already receiving entecavir and continuing entecavir with treatment.

NCT ID: NCT02726022 Completed - Clinical trials for Hepatitis C, Chronic

A Quality of Life Study of Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) and Persistently Normal Alanine Aminotransferase (ALT) Levels

Start date: February 2007
Phase: N/A
Study type: Observational

Participants with CHC and normal ALT, who have been under treatment with peginterferon alfa-2a and ribavirin for at least 4 weeks, will be enrolled into this non-interventional, open-label study. The primary aim is to evaluate quality of life according to the Short Form 36 (SF-36) questionnaire, modified for the Greek population.

NCT ID: NCT02725866 Completed - Chronic Hepatitis C Clinical Trials

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

Start date: April 5, 2016
Phase:
Study type: Observational

The interferon-free combination regimen of paritaprevir/ritonavir/ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well-controlled conditions. This observational study is the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to the local label, under real-world conditions in Greece in a clinical practice patient population.

NCT ID: NCT02723084 Completed - Hepatitis C Virus Clinical Trials

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

CERTAIN-2
Start date: April 8, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this phase 3 study is to evaluate the efficacy and safety of ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for 12 weeks in Hepatitis C Virus (HCV) Genotype 2 (GT2) infected participants.